KPV

KPV, also known as KPV tripeptide, Lys-Pro-Val, or alpha-MSH fragment 11-13, is an anti-inflammatory peptide that has garnered significant interest in research settings for its potential therapeutic applications. This tripeptide is derived from alpha-melanocyte stimulating hormone (alpha-MSH) and represents a specific fragment comprising amino acids 11-13 of the parent hormone. The mechanism of action for KPV centres on its ability to bind to melanocortin receptors, particularly MC1R and MC3R. Through this receptor interaction, KPV initiates a cascade of anti-inflammatory responses within research models. Studies indicate that this binding leads to the inhibition of pro-inflammatory cytokine production whilst simultaneously promoting the release of anti-inflammatory cytokines. Additionally, research has demonstrated that KPV reduces oxidative stress and modulates immune cell activity, contributing significantly to its overall anti-inflammatory properties. In laboratory studies, KPV has shown promising effects across several key areas of inflammation research. Research models have demonstrated its ability to reduce inflammation in the gut, making it particularly relevant for gastrointestinal inflammation studies. Furthermore, investigations have shown that KPV decreases systemic inflammatory markers, suggesting broader anti-inflammatory potential beyond localised effects. Of particular interest to researchers is KPV's demonstrated ability to promote healing of intestinal mucosa in research models. This property, combined with its immune response modulation capabilities, positions KPV as a valuable tool for studying inflammatory conditions and tissue repair mechanisms. The peptide's capacity to reduce oxidative stress adds another dimension to its research applications, particularly in studies examining the relationship between inflammation and cellular damage. Currently, the evidence grade for KPV is classified as C, reflecting that most available data comes from animal studies and in vitro experiments rather than human clinical trials. Whilst these studies have consistently shown anti-inflammatory effects, human trials are needed to confirm efficacy and safety in clinical settings.